arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Veradermics, Inc

MANE
$128.53 ▼ -8.16 (-5.97%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
3 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
89
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Veradermics, Inc shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $95.8M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 59.8% ↗
FCF / Share $-96.14 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

3-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-70.00M
↓ -164.3% —
FCF / Share Free cash flow per share
$-96.14
↓ -199.1% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↑
98
Cash Quality ↑
67

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 3 years · 7 quarters